Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

Dr Rahul Aggarwal - University of California, San Francisco, USA
Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC ( Dr Rahul Aggarwal - University of California, San Francisco, USA )
26 Jun 2026

First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML

Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML ( Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany )
22 Jun 2026

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA
Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )
30 May 2026

Omission of axillary lymph node dissection reduces arm morbidity without compromising survival in select breast cancer cases

Dr Jana de Boniface - Capio St. Göran's Hospital, Stockholm, Sweden
Omission of axillary lymph node dissection reduces arm morbidity without compromising survival in select breast cancer cases ( Dr Jana de Boniface - Capio St. Göran's Hospital, Stockholm, Sweden )
30 May 2026

Combination therapeutic strategies for aRCC patients with bone metastases

Prof Stéphane Oudard and Dr Stefanie Zschäbitz
Combination therapeutic strategies for aRCC patients with bone metastases ( Prof Stéphane Oudard and Dr Stefanie Zschäbitz )
13 May 2026

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer

Prof Nicolas Girard - Institut Curie, Paris, France
Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )
14 Apr 2026

Distinct lung microbiome patterns identified in Portuguese patients with lung cancer

Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal
Distinct lung microbiome patterns identified in Portuguese patients with lung cancer ( Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal )
14 Apr 2026

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte
EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )
18 Mar 2026

Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer

Dr Dalia Kaakour - University of California, Irvine, USA
Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer ( Dr Dalia Kaakour - University of California, Irvine, USA )
18 Mar 2026